<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We measured the thickness of the substantia innominata using magnetic resonance imaging in 122 patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), 31 patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>) and 34 patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD), and examined the correlates of cognitive response to <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0000726'>dementia</z:hpo> groups showed significant <z:mpath ids='MPATH_127'>atrophy</z:mpath> of the substantia innominata compared to 28 age-matched controls, <z:mpath ids='MPATH_127'>atrophy</z:mpath> was greater in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> group, but less in the VaD group than the AD group </plain></SENT>
<SENT sid="2" pm="."><plain>Mini-Mental State Examination score changes at 12 weeks after <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> administration inversely and significantly correlated with the thickness of the substantia innominata in patients with AD (n=103, r=-0.43, p&lt;0.0001) and in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> (n=24, r=-0.57, p&lt;0.01), but not in patients with VaD (n=12, r=-0.22, p&gt;0.1) </plain></SENT>
<SENT sid="3" pm="."><plain>There may be some differences in cholinergic impairment among AD, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> and VaD, reflecting cholinergic neuropathology </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical response to cholinergic therapy may be partly attributable to damaged cholinergic neurons in AD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>, but not in VaD, suggesting differences in the therapeutic implication of cholinergic system degeneration </plain></SENT>
</text></document>